Oncology Nursing News®

Breast Cancer

FDA Accepts BLA for Sacituzumab Govitecanto Treat TNBC

FDA Accepts BLA for Sacituzumab Govitecanto Treat TNBC

BY STAFF

FDA Approves Trastuzumab Deruxtecan for HER2+ Breast Cancer

FDA Approves Trastuzumab Deruxtecan for HER2+ Breast Cancer

BY GINA COLUMBUS

FDA Grants Tucatinib Breakthrough Therapy Designation Breast Cancer Subset

FDA Grants Tucatinib Breakthrough Therapy Designation Breast Cancer Subset

BY JASON M. BRODERICK

AE Management Could Affect Compliance in Breast Cancer Treatment

AE Management Could Affect Compliance in Breast Cancer Treatment

BY MADELINE KUIPER, MSN, RN, OCN

Breast Cancer Outcomes Can Be Predicted by Residual Cancer Burden

Breast Cancer Outcomes Can Be Predicted by Residual Cancer Burden

BY KRISTI ROSA

Neoadjuvant Durvalumab Is Promising for TNBC Treatment

Neoadjuvant Durvalumab Is Promising for TNBC Treatment

BY JASON M. BRODERICK

Palbociclib Shows OS Benefit in Frontline HR+/HER2- Breast Cancer

Palbociclib Shows OS Benefit in Frontline HR+/HER2- Breast Cancer

BY JASON M. BRODERICK

T-DXd Could Be New Standard of Care for Breast Cancer Subset

T-DXd Could Be New Standard of Care for Breast Cancer Subset

BY KRISTIE L. KAHL

FDA Approves Generic Everolimus Tablets

FDA Approves Generic Everolimus Tablets

BY KRISTI ROSA

Overcoming AI Resistance in ESR1-Mutant Breast Cancer

Overcoming AI Resistance in ESR1-Mutant Breast Cancer

BY CAROLINE SEYMOUR

External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc

OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives

About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.